[  1] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[  2] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[  3] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[  4] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[  5] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[  6] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[  7] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[  8] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[  9] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 10] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 11] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 12] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 13] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 14] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 15] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[ 16] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 17] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 18] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 19] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 20] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 21] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 22] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 23] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[ 24] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 25] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 26] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 27] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 28] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 29] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 30] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 31] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[ 32] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 33] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 34] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 35] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 36] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 37] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 38] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 39] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[ 40] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 41] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 42] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 43] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 44] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 45] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 46] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 47] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[ 48] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 49] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 50] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 51] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 52] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 53] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 54] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 55] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 56] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 57] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[ 58] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 59] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 60] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 61] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 62] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 63] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 64] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 65] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 66] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 67] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 68] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[ 69] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 70] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 71] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 72] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 73] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 74] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 75] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 76] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 77] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 78] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[ 79] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 80] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[ 81] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 82] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 83] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 84] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 85] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 86] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 87] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 88] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 89] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 90] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[ 91] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[ 92] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 93] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[ 94] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[ 95] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[ 96] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 97] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[ 98] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[ 99] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[100] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[101] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[102] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[103] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[104] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[105] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[106] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[107] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[108] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[109] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[110] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[111] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[112] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[113] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[114] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[115] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[116] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[117] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[118] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[119] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[120] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[121] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[122] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[123] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[124] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[125] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[126] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[127] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[128] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[129] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[130] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[131] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[132] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[133] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[134] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[135] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[136] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[137] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[138] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[139] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[140] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[141] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[142] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[143] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[144] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[145] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[146] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[147] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[148] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[149] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[150] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[151] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[152] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[153] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[154] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[155] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[156] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[157] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[158] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[159] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[160] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[161] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[162] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[163] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[164] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[165] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[166] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[167] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[168] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[169] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[170] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[171] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[172] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[173] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[174] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[175] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[176] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[177] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[178] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[179] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[180] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[181] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[182] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[183] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[184] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[185] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[186] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[187] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[188] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[189] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[190] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[191] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[192] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[193] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[194] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[195] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[196] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[197] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[198] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[199] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[200] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[201] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[202] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[203] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[204] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[205] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[206] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[207] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[208] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[209] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[210] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[211] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[212] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[213] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[214] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[215] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[216] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[217] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[218] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[219] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[220] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[221] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[222] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[223] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[224] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[225] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[226] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[227] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[228] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[229] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[230] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[231] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[232] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[233] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[234] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[235] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[236] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[237] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[238] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[239] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[240] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[241] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[242] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[243] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[244] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[245] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[246] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[247] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[248] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[249] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[250] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[251] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[252] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[253] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[254] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[255] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[256] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[257] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[258] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[259] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[260] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[261] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[262] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[263] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[264] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[265] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[266] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[267] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[268] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[269] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[270] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[271] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[272] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[273] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[274] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[275] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[276] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[277] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[278] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[279] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[280] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[281] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[282] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[283] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[284] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[285] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[286] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[287] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[288] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[289] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[290] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[291] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[292] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[293] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[294] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[295] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[296] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[297] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[298] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[299] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[300] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[301] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[302] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[303] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[304] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[305] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[306] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[307] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[308] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[309] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[310] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[311] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[312] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[313] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[314] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[315] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[316] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[317] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[318] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[319] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[320] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[321] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[322] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[323] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[324] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[325] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[326] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[327] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[328] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[329] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[330] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[331] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[332] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[333] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[334] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[335] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[336] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[337] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[338] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[339] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[340] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[341] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[342] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[343] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[344] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[345] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[346] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[347] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[348] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[349] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[350] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[351] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[352] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[353] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[354] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[355] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[356] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[357] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[358] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[359] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[360] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[361] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[362] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[363] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[364] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[365] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[366] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[367] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[368] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[369] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[370] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[371] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[372] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[373] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[374] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[375] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[376] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[377] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[378] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[379] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[380] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[381] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[382] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[383] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[384] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[385] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[386] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[387] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[388] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[389] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[390] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[391] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[392] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[393] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[394] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[395] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[396] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[397] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[398] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[399] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[400] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[401] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[402] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[403] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[404] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[405] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[406] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[407] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[408] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[409] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[410] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[411] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[412] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[413] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[414] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[415] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[416] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[417] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[418] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[419] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[420] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[421] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[422] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[423] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[424] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[425] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[426] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[427] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[428] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[429] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[430] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[431] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[432] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[433] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[434] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[435] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[436] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[437] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[438] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[439] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[440] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[441] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[442] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[443] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[444] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[445] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[446] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[447] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[448] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[449] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[450] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[451] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[452] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[453] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[454] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[455] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[456] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[457] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[458] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[459] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[460] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[461] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[462] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[463] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[464] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[465] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[466] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[467] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[468] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[469] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[470] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[471] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[472] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[473] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[474] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[475] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[476] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[477] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[478] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[479] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[480] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[481] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[482] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[483] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[484] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[485] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[486] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[487] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[488] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[489] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[490] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[491] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[492] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[493] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[494] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[495] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[496] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[497] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[498] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[499] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[500] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[501] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[502] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[503] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[504] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[505] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[506] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[507] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[508] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[509] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[510] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[511] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[512] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[513] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[514] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[515] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[516] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[517] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[518] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[519] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[520] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[521] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[522] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[523] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[524] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[525] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[526] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[527] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[528] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[529] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[530] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[531] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[532] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[533] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[534] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[535] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[536] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[537] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[538] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[539] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[540] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[541] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[542] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[543] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[544] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[545] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[546] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[547] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[548] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[549] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[550] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[551] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[552] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[553] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[554] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[555] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[556] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[557] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[558] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[559] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[560] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[561] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[562] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[563] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[564] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[565] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[566] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[567] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[568] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[569] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[570] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[571] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[572] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[573] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[574] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[575] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[576] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[577] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[578] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[579] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[580] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[581] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[582] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[583] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[584] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[585] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[586] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[587] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[588] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[589] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[590] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[591] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[592] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[593] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[594] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[595] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[596] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[597] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[598] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[599] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[600] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[601] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[602] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[603] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[604] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[605] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[606] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[607] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[608] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[609] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[610] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[611] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[612] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[613] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[614] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[615] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[616] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[617] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[618] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[619] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[620] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[621] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[622] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[623] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[624] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[625] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[626] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[627] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[628] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[629] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[630] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[631] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[632] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[633] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[634] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[635] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[636] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[637] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[638] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[639] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[640] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[641] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[642] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[643] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[644] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[645] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[646] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[647] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[648] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[649] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[650] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[651] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[652] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[653] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[654] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[655] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[656] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[657] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[658] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[659] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[660] Press Release (2026-02-06)/Jubilant Pharmova Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Press Release alongwith Earnings Presentation on the financials and operational performance of the Company for the quarter and nine months ended December 31, 2025".
[661] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[662] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[663] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[664] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[665] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[666] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[667] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[668] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[669] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[670] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[671] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[672] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[673] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[674] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[675] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[676] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[677] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[678] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[679] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[680] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[681] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[682] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[683] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[684] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[685] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[686] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[687] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[688] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[689] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[690] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[691] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[692] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[693] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[694] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[695] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[696] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[697] Press Release (2026-02-06)/Jubilant Pharmova Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Press Release alongwith Earnings Presentation on the financials and operational performance of the Company for the quarter and nine months ended December 31, 2025".
[698] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[699] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[700] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[701] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[702] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[703] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[704] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[705] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[706] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[707] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[708] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[709] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[710] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[711] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[712] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[713] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[714] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[715] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[716] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[717] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[718] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[719] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[720] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[721] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[722] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[723] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[724] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[725] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[726] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[727] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[728] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[729] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[730] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[731] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[732] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[733] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[734] Press Release (2026-02-06)/Jubilant Pharmova Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Press Release alongwith Earnings Presentation on the financials and operational performance of the Company for the quarter and nine months ended December 31, 2025".
[735] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[736] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[737] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-10)/Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.
[738] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[739] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[740] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[741] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[742] Press Release (2026-02-06)/Solara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."
[743] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[744] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[745] Analysts/Institutional Investor Meet/Con. Call Updates (2025-05-17)/Morepen Laboratories Limited has informed the Exchange about Transcript
[746] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[747] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[748] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[749] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IPCA Laboratories Limited has informed the Exchange about Transcript
[750] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[751] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[752] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Orchid Pharma Limited has informed the Exchange about Transcript
[753] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[754] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-12)/Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
[755] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[756] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[757] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[758] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[759] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-14)/Divi's Laboratories Limited has informed the Exchange about Transcript
[760] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-16)/Aarti Pharmalabs Limited has informed the Exchange about Transcript
[761] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[762] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[763] Press Release (2026-02-11)/Hikal Limited has informed the Exchange regarding a press release dated February 11, 2026, titled "Q3 FY26 Earnings Release".
[764] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[765] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-17)/Hikal Limited has informed the Exchange about Transcript
[766] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[767] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[768] Analysts/Institutional Investor Meet/Con. Call Updates (2026-02-18)/IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
[769] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[770] Analysts/Institutional Investor Meet/Con. Call Updates (2025-11-19)/Natural Capsules Limited has informed the Exchange about Transcript
[771] Press Release (2026-02-06)/Jubilant Pharmova Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Press Release alongwith Earnings Presentation on the financials and operational performance of the Company for the quarter and nine months ended December 31, 2025".